Pharma Monthly Update - November 2011 - PINC Sector Report

DOMESTIC:

- Pfizer, Ranbaxy sued by 11 California Pharmacies over Lipitor prices
- Ranbaxy gets approval for first antimalarial combination drug developed by an Indian Pharma Company
- DRL seeks denotification of Special Economic Zone at Medak
- Strike at DRL's Srikakulam manufacturing unit has been called off
- Raging Capital and Permian Investment partners oppose Sun Pharma's offer to acquire Taro
- Lupin sued in US for Lumigan patent infringement
- Lupin acquires I'rom Pharma in Japan
- Glenmark receives USD5mn payment from Sanofi-Aventis
- Glenmark enters cosmeceutical segment through a ten-year agreement with Immanence-IDC
- Piramal Healthcare settles patent litigation with Baxter Healthcare
- Piramal Healthcare seeks shareholders' nod for IT, Security and other biz
- Aurobindo, Pfizer reach accord in Lipitor patent case
- TCG ties up with JSW Lifesciences for drug clinical studies
- Hospira received approval for generic Imipenem-Cilastatin, expected to benefit its API supplier, Orchid Chemicals
- Bayer withdraws writ petition against Natco over compulsory licensing of Nexavar

GLOBAL:

- Pfizer aims to keep one third of Lipitor pie
- Teva loses court bid to halt Watson's Seasonique copy
- Teva and P&G launch OTC joint venture called PGT Healthcare
- Mylan pays USD17.5mn to buy rights to develop Pfizer's generic version of Advair
- USFDA warns Mylan over Puerto Rico plant violations
- Watson wins Kentucky drug pricing litigation
- Watson launches authorized generic version of Lipitor in US
- US Court favours GSK in Arzerra patent infringement lawsuit
- Impax sued by Teva's Cephalon over Fentora pain drug patents

INDUSTRY:

- NPPA has issued demand notice of Rs23.6bn for drug overcharging to Indian Pharma companies.

Source : Equity Bulls

Keywords